checkAd

     137  0 Kommentare Inspire Medical Systems, Inc. Announces Exclusive Distribution Agreement with Japan Lifeline Co., Ltd to Commercialize Inspire Therapy in Japan - Seite 2

    Japan is one of the largest markets for medical technologies in the world and recent published data indicates that approximately 9 million Japanese have an Apnea Hypopnea Index (“AHI”) greater than 15, which qualifies them at least as moderate OSA patients.

    About Inspire Medical Systems

    Inspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

    For additional information about Inspire, please visit www.inspiresleep.com.

    About Japan Lifeline Co., Ltd.

    Japan Lifeline is a manufacturer and full-service distributor of medical devices specializing in the cardiovascular space with a track record of about 40 years in Japan. The company's proprietary products developed based on its wealth of experience of arrhythmias and cardiovascular surgery have been highly evaluated, and the company holds a top-class market share in Japan. Japan Lifeline is a publicly traded company, ticker symbol 7575 (TSE 1st Section).

    For more information about Japan Lifeline, please visit www.japanlifeline.com.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the expected timing of the formal listing of Inspire therapy in the Japan National Health Insurance Payment Listing and the first implants of the Inspire therapy in Japan, and our ability to realize the anticipated benefits of the planned commercialization of Inspire therapy in Japan. In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ “future,” “outlook,” “guidance,” ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential,’’ ‘‘continue,’’ or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words.

    Seite 2 von 3



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Inspire Medical Systems, Inc. Announces Exclusive Distribution Agreement with Japan Lifeline Co., Ltd to Commercialize Inspire Therapy in Japan - Seite 2 Reimbursement Review of Inspire Therapy Completed by Japan Ministry of Health Labour and Welfare (MHLW); National Health Insurance Payment Listing Expected in June 2021 Initial Inspire Therapy Implants in Japan Anticipated to Occur in Second Half …